Phase 4 N=40 Effects of Modafinil in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
Phase 2 N=35 Studying Amphetamine Withdrawal in Humans
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Phase 2 N=52 Varenicline for Methamphetamine Dependence
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: End of Treatment Abstinence — 5; 4 Participants
N/A N=8 Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Phase 2 N=140 Topiramate for the Treatment of Methamphetamine Dependence - 1
Methamphetamine
Primary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants
Phase 2 N=204 Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Number of Subjects Showing Abstinence — 14; 20 Participants
Phase 2 N=13 Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05
Phase 2 N=15 Open-Label Disulfiram for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Phase 2 N=20 Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: Change in MA Positive Urine Drug Screens Among Participants Randomly Assigned to Receive Varenicline Versus Placebo. — 7.4; 2.3 total MA-free urine drug screens
Phase 2 N=71 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens
Phase 2 N=8 Safety and Tolerability of Modafinil for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Heart Rate — 79.66 beats per minute
Phase 3 N=104 Citicoline Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Methamphetamine Dependent Subjects Treated With Citicoline vs Placebo — 0.3025; 0.3850 total amount consumed in grams
Phase 2 N=210 Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Abstinence (Week 1 - 12) — 27; 14; 38; 13 Participants
Phase 1 N=12 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Phase 2 N=90 Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
Substance Abuse · HIV Infections
Primary: To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals. — 44…
Phase 2 N=125 Trial of Ibudilast for Methamphetamine Dependence
Methamphetamine Dependence · HIV Infection
Primary: Methamphetamine Use — 9; 10 Participants
Phase 2 N=217 Intensive Motivational Interviewing for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Methamphetamine Days of Abstinence : Proportion of Days Abstinent — .56; .55; .74; .74 proportion of days abstinent — p=.47
Phase 4 N=65 A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
Depression · Dual Diagnosis · Drug Addiction
Primary: Hamilton Depression Rating Scale (HAMD) Scores — 16.76; 17.65; 1.67; 16.24 score on a scale
Phase 1 N=9 Buspirone as a Candidate Medication for Methamphetamine Abuse
Methamphetamine Dependence · Methamphetamine Abuse
Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses
Phase 2 N=72 A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
Methamphetamine Dependence, Treatment Seeking
Primary: Methamphetamine Abstinence
Phase 2 N=30 Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM
Substance Abuse · HIV Infections
Primary: Feasibility: Proportion of Persons Screened Who Are Eligible and Enrolled — 30 Eligible persons screened who enrolled
Phase 4 N=14 Creatine as a Treatment Option for Depression in Methamphetamine Using Females
Depression · Substance Abuse · Substance Use
Primary: HAMD Rating Scores — 16.86; 10.71; 9.81; 7.33 Units on a scale
Phase 2 N=45 N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Penn Craving Scale — 24.0; 24.0; 21.1 units on a scale
Phase 3 N=403 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Methamphetamine Use Disorder
Primary: Number of Participants With Treatment Response During Medication Phase at Stage 1 — 10; 18; 284; 91 Participants
Phase 2 N=49 Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
Methamphetamine Use Disorder
Primary: Participants Categorized as "Responders" — 11 Participants
Phase 4 N=26 Effects of Genotype on Resting State Connectivity During Methamphetamine Administration
Methamphetamine-dependence
Primary: Functional Connectivity During Resting State Magnetic Resonance Imaging (MRI) — 0.91; 0.52; 0.54; 0.32 Fisher's Z-score
Phase 2 N=73 Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…
N/A N=119 Long-term Behavior Change - 1
Amphetamine-related Disorders
Primary: Methamphetamine Use During Intervention — 65.17; 60.35; 57.74; 42.81 percentage of negative urine samples — p=<0.01